This is the authors' abstract. We don't add key points for this paper.
The clinical data of 459 patients, who were first diagnosed as HIV/HBV co-infection from January 2007 to December 2013, were retrospectively analyzed. Among all patients, there were 89 cases with CD4 < 50/μl, 134 cases with CD4 50-200/μl and 236 cases with CD4﹥200/μl , when HIV infection was diagnosed. In these three groups with different CD4 levels, the HBV DNA positive rates were 49.3% (37/75), 50.5% (54/107) and 33.7%(66/196); the HBV viral load were (6.37±1.71) log10 copies/ml, (5.82±1.86) log10 copies/ml and (4.36±1.64) log10 copies/ml; the rates of abnormal liver function were 29.2%(26/89), 29.1%(39/134) and 10.6%(25/236); the occurrence rates of end-stage-liver-diseases were 16.9% (15/89), 14.9% (20/134) and 5.1%(12/236); the mortality rates were 10.1% (9/89), 9.7%(13/134) and 3.8%(9/236), respectively. The HBV DNA positive rates, HBV viral load, the rates of abnormal liver function, the occurrence rates of end-stage-liver-diseases and the mortality rates in CD4﹥200/μl group were lower than that in CD4 < 50/μl group and 50-200/μl group. The results suggest that for HIV and HBV co-infection patients, HBV replication level and prognosis of liver diseases are associated with CD4+ T lymphocyte count.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2016) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: